mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say. Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More
etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders. Funded by Flanders Innovation & Entrepreneurship (VLAIO), the project aims to combine etherna’s vast expertise in developing customised mRNA and lipid-based nanoparticle technologies for immuno-modulation with UHasselt’s research… Read More
The strengths of etherna’s lipid based nanoparticle (LNP) platform have been showcased in a peer-reviewed paper in Advanced Functional Materials. etherna’s Vice President, Technology & Innovation, Stefaan De Koker described the paper as a “landmark” for the company and its technology. The RNA… Read More
etherna, an mRNA/LNP technologies company, has announced that Bernard Sagaert has been confirmed as Chief Executive Officer. At the same time Marijn Dekkers, an existing Board Member representing investor Novalis LifeSciences LLC, has been appointed Chairman of the Board. Sagaert’s appointment follows an interim 12-month period during… Read More
